Free Trial
NASDAQ:NDRA

ENDRA Life Sciences Q2 2026 Earnings Results & Report

ENDRA Life Sciences logo
$4.41 -0.23 (-4.96%)
Closing price 11/13/2026 03:57 PM Eastern
Extended Trading
$4.46 +0.05 (+1.25%)
As of 11/13/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ENDRA Life Sciences beat analyst earnings expectations in its Q2 2026 results, released August 14, 2026. The company reported EPS of -$0.63 versus the -$0.84 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

ENDRA Life Sciences EPS Results

Actual EPS
-$0.63
Consensus EPS
-$0.84
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 5 quarters

ENDRA Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$100 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

ENDRA Life Sciences Q2 2026 Earnings FAQ

ENDRA Life Sciences (NASDAQ:NDRA) reported earnings of -$0.63 per share for Q2 2026, beating the consensus estimate of -$0.84. The report was announced on Friday, August 14, 2026.

ENDRA Life Sciences Earnings Headlines

A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
See More ENDRA Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ENDRA Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ENDRA Life Sciences and other key companies, straight to your email.

About ENDRA Life Sciences

ENDRA Life Sciences (NASDAQ:NDRA), Inc. (NASDAQ: NDRA) is a medical technology company developing noninvasive diagnostic tools for tissue characterization. The company’s lead technology is Thermo-Acoustic Enhanced Ultrasound (TAEUS), which is designed to enhance conventional ultrasound systems with additional information about tissue properties.

ENDRA is initially applying TAEUS to the assessment of liver disease, including the detection and measurement of liver fat associated with conditions such as nonalcoholic fatty liver disease. The technology is intended to work with existing ultrasound equipment and could provide clinicians with a more accessible alternative to certain imaging procedures that are more expensive, less widely available, or involve ionizing radiation.

Based in Ann Arbor, Michigan, ENDRA has focused its development activities on expanding the capabilities of ultrasound imaging for use in routine clinical settings. TAEUS remains an investigational technology, and its availability and permitted uses depend on regulatory authorization in the applicable market.

View ENDRA Life Sciences Profile